BioDelivery Sciences reports first quarter loss
05/09/2014 12:04 PM
02/15/2015 11:18 AM
BioDelivery Sciences International reported late late Thursday a narrower net loss in the first quarter.
The company had a net loss of $4.6 million, or 11 cents per share, compared with a net loss of $12.7 million, or 34 cents per share, in the first quarter of 2013.
Revenue was $20.7 million, compared with $1.6 million in the first quarter last year.
Research and development expenses increased from $12 million to $14.6 million last year. The increase was attributed to additional costs associated with the development of BEMA Buprenorphine, the company's experimental treatment for chronic pain, and Clonidine Topical Gel, a treatment for painful diabetic neuropathy, a condition that afflicts some people suffering from diabetes.
In February, BioDelivery Sciences raised $60 million by selling a block of shares to a group of institutional investors. The proceeds are to pay for the commercialization of Bunavail, a treatment for opioid dependence,.
The company has filed a new drug application for Bunavail and expects to hear back from the Food and Drug Administration on June 7. BioDelivery Sciences has also begun enrolling patients in Phase 3 trials of Clonidine. The company signed a licensing deal to develop the drug last year, which it forecasts could have annual peak sales of more than $300 million.
As of March 1, BioDelivery Sciences had $88.2 million in cash, compared with $23.2 million during the same period last year.
“There has never been a more exciting time at BDSI as we move closer to ... June 7th and the potential launch of Bunavail this year, as well as the data read out of our second pivotal trial for BEMA Buprenorphine for chronic pain in early July,” CEO Mark Sirgo said in a statement.
The company's shares, which opened at $8.40 Friday, were down about 2 percent in afternoon trading.
Join the Discussion
News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.